Cassava Sciences | PTIE - Ebitda


Cassava Sciences reported $-11.73M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Eisai JPY 23.48B 14.68B Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Geron USD -7.55M 8.85M Jun/2025
J&J USD 9.52B 389M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024